Yes, Melanotan II has become increasingly popular due to growing interest in peptide-related wellness and advanced research applications.
Glucose-lowering drugs and liver-related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population-based studies
For people aged 18-29, only 1% had ever used GLP-1 drugs to treat chronic conditions, while 7% of those in this age group had used them for weight loss, and a further 3% had used them for chronic conditions and weight loss
This is why GLP-1 protocols are increasingly described as metabolic interventions, not just appetite suppressants
Mechanistic Advantages: Rapid Onset: Achieves 10% weight loss within 12 weeks, swiftly mitigating complication risks (e.g., sleep apnea, heart failure)
For more updates, one can follow Watsons' social media pages on Facebook and Instagram at @watsonsph